Effects of Proton Pump Inhibitor on Gastroesophageal Varices of Cirrhosis: A Randomized Controlled Trial

BackgroundThe use of proton pump inhibitor (PPI) for gastroesophageal varices in patients with cirrhosis after endoscopic therapy remains controversial. This study aimed to evaluate the effect of PPI on gastroesophageal varices in patients with cirrhosis after endoscopic therapy, including variceal bleeding and adverse events.MethodsBetween May 2017 and June 2019, cirrhotic patients with gastroesophageal varices confirmed by endoscopy were considered for enrollment in this study. Eligible subjects were randomized into two groups: one group received PPI for 14 days and the other group did not undergo PPI treatment. Patients were followed up for 8 weeks.ResultsDuring the follow-up period, three patients (3/53, 5.66%) in the PPI group experienced variceal bleeding on day 9, 16, and 25 after endoscopic therapy, including one patient with primary prophylaxis and two with acute bleeding. In the non-PPI group, three patients (3/56, 5.66%) suffered from variceal bleeding on day 7, 42, and 56 after endoscopic therapy, including two patients with secondary prophylaxis and one with acute bleeding (P>0.99). The rate of adverse events was similar between the two groups (38% vs. 28%, P=0.30). Furthermore, the average hospitalization expense of patients in the PPI group was higher than that of patients in the non-PPI group ($2305 vs. $3096, P<0.001).ConclusionsPPI does not appear to reduce variceal bleeding and adverse events in patients with cirrhosis after endoscopic therapy.Trial registration: This trial was registered with ClinicalTrials.gov (NCT 03175731, 05/06/2017).

[1]  Y. Chan,et al.  Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis , 2019, World journal of gastroenterology.

[2]  P. Andersen,et al.  Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[3]  S. Saligram,et al.  Update on the management of gastrointestinal varices , 2019, World journal of gastrointestinal pharmacology and therapeutics.

[4]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2019, Clinical Liver Disease.

[5]  A. Farcomeni,et al.  Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis , 2018, Hepatology.

[6]  A. Waness,et al.  Increased Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Using Proton Pump Inhibitors , 2018, GE - Portuguese Journal of Gastroenterology.

[7]  F. Chan,et al.  Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018 , 2018, Gut.

[8]  X. Qi,et al.  Acid suppression in patients treated with endoscopic therapy for the management of gastroesophageal varices: a systematic review and meta-analysis , 2018, Expert review of gastroenterology & hepatology.

[9]  R. Chung,et al.  Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES , 2018, Alimentary pharmacology & therapeutics.

[10]  Y. Seo.  Prevention and management of gastroesophageal varices , 2017, Clinical and molecular hepatology.

[11]  Deng-Chyang Wu,et al.  The Role of Adjuvant Acid Suppression on the Outcomes of Bleeding Esophageal Varices after Endoscopic Variceal Ligation , 2017, PloS one.

[12]  J. Bosch,et al.  Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases , 2017, Hepatology.

[13]  K. Sugano,et al.  Evidence-based clinical practice guidelines for liver cirrhosis 2015 , 2016, Journal of Gastroenterology.

[14]  B. Kronenberger,et al.  Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis , 2015, Alimentary pharmacology & therapeutics.

[15]  J. Cha,et al.  Proton pump inhibitor administration delays rebleeding after endoscopic gastric variceal obturation. , 2014, World journal of gastroenterology.

[16]  C. Tai,et al.  Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding , 2013, Journal of gastroenterology and hepatology.

[17]  F. Manguso,et al.  The Effectiveness of Current Acute Variceal Bleed Treatments in Unselected Cirrhotic Patients: Refining Short-Term Prognosis and Risk Factors , 2012, The American Journal of Gastroenterology.

[18]  S. Tanabe,et al.  Long-term administration of PPI reduces treatment failures after esophageal variceal band ligation: a randomized, controlled trial , 2012, Journal of Gastroenterology.

[19]  N. Chavez-Tapia,et al.  PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis. , 2010, World journal of gastroenterology.

[20]  L. Welage,et al.  Continuous Infusion of Pantoprazole with Octreotide Does Not Improve Management of Variceal Hemorrhage , 2009, Pharmacotherapy.

[21]  N. Shaheen,et al.  Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: A randomized, controlled trial , 2005, Hepatology.

[22]  P. Hayes,et al.  UK guidelines on the management of variceal haemorrhage in cirrhotic patients , 2000, Gut.

[23]  T. Sauerbruch,et al.  [Treatment of portal hypertension]. , 1995, Medizinische Klinik.

[24]  M. Djaldetti,et al.  The effect of pH on platelet and coagulation factor activities. , 1978, American journal of surgery.